EMERGENT BIOSOLUTIONS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
EMERGENT BIOSOLUTIONS INC. (EBS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-04.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2017-08-04
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2017-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2017-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2016-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2016-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2016 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2015 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2014 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2013 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | $0.00 derived: sum of 3 quarters · filed 2017-08-04 | $0.00 derived: sum of 4 quarters · filed 2017-08-04 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | $0.00 derived: sum of 2 quarters · filed 2017-05-05 | $0.00 derived: sum of 3 quarters · filed 2017-05-05 | $0.00 derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | $0.00 derived: sum of 4 quarters · filed 2017-02-28 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 derived: sum of 4 quarters · filed 2017-02-28 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-06 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | $0.00 10-Q · filed 2015-11-06 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 10-K · filed 2015-03-09 | ||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-08 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-03-10 | |||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-03 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |